Growth Factor Therapy for Tissue Repair in Reno, NV

CDC PLACES vs. JE: two files, not one brochure

Adult obesity in Reno is 28.4% (CDC PLACES 2023). That shows up in wound offloading and in joint-preservation volume — not as a slogan. CDC PLACES (2023, crude) estimates 9.5% of adults in Reno have diagnosed diabetes — 2.5 points below the U.S. 12% figure. Nevada is outside CDC’s core Diabetes Belt list; use the PLACES city rate anyway. Hawk Medical is the distributor for growth factor therapy, not a walk-in clinic.

Where Reno programs actually stall

• CDC PLACES (2023, crude) estimates 9.5% of adults in Reno have diagnosed diabetes — 2.5 points below the U.S. 12% figure. Adult arthritis here is 23.7% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Separate 361 tissue, PRP, and CTP tickets before you market growth factor therapy in Reno. Mixing lanes is how recoupments start.
• Nevada is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).
• Chronic wounds that stall past 30 days are the typical entry point for cellular/tissue products. CDC diabetes prevalence is the epidemiologic backdrop; JE coverage rules are the billing backdrop. Both have to be true on the same chart.

Uninsured mix and Medicare CTPs in the same building

America’s Health Rankings (BRFSS 2024) only publishes state diabetes as a range nationally (Colorado 8.4% to West Virginia 18.4%). For Reno we use CDC PLACES instead of interpolating a fake city rate from that range. CDC PLACES (2023, crude) estimates 9.5% of adults in Reno have diagnosed diabetes — 2.5 points below the U.S. 12% figure.

How we’d stand this up in clinic